The insulin-like growth factor-system in a patient with diffuse large B-cell non-hodgkin's lymphoma and lactic acidosis

Annals of Clinical Biochemistry

Volumn 50, Issue 2, 2013, Pages 169-172

  Hoogwerf, Demelza ^a   van Doorn, Jaap ^b   Maartense, Eduard ^a  

^a Department of Internal Medicine Reinier de Graaf Gasthuis ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; INSULIN; LACTATE DEHYDROGENASE; LOMUSTINE; PREDNISOLONE; RITUXIMAB; SOMATOMEDIN; VINCRISTINE;

ABDOMINAL SWELLING; AGED; ARTICLE; ASCITES; ASCITES FLUID; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOPATHOLOGY; DYSPNEA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FOLLOW UP; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LARGE CELL LYMPHOMA; MALE; MEDIASTINUM LYMPH NODE; MEDICAL HISTORY; METABOLIC REGULATION; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULSE RATE; SWEATING; TRANSVERSE COLON;

ACIDOSIS, LACTIC; AGED; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; SOMATOMEDINS;

EID: 84879456757     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2012.012125     Document Type: Article

References (29)

1. Scheerer PP, Pierre RV, Schwartz DL, Linman JW. Reed-Sternberg-cell leukemia and lactic acidosis; unusual manifestations of Hodgkin's disease. N Engl J Med 1964;270:274-8
2. Lee HS, Kim HJ, Choi S, et al. A case of type B lactic acidosis in acute leukemia. Yonsei Med 2010;51:460-2
3. Sillos EM, Shenep JL, Burghen GA, Pui CH, Behm FG, Sandlund JT. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer 2001;92:2237-46
4. Mazurek S, Boschek CB, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr 1997;29:315-30
5. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997;29:339-43
6. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Psysiol 1993;55:131-53
7. Osorio S, Bernis C, de La Cámara R. Lactic acidosis in Non-Hodgkin's lymphoma ad response to chemotherapy. Haematologica 2002;87:ELT05
8. Friedenberg AS, Brandoff DE, Schiffman FJ. Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review. Medicine 2007;87:225-32
9. Ruiz JP, Singh AK, Hart P. Type B lactic acidosis secondary to malignancy: case report, review of published cases, insights into pathogenesis, and prospects for therapy. Sci World J 2011;11:1316-24
10. Luft FC. Lactic acidosis update for critical care clinicians. J Am Soc Nephrol 2001;12(Suppl. 17):S15-19
11. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997;18:801-31
12. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 2011;47:R1-10
13. Rastogi MV, Desai N, Quintos JB. Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma. J Pediatr Endocrinol Metab 2008;21:805-10
14. de Groot JW, Rikhof B, van Doorn J, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer 2007;14:979-93
15. Brü ngger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: new cause of growth hormone insensitivity in humans. Kidney Int 1997;51:216-21
16. Wiederkehr M, Krapf R. Metabolic and endocrine effects of metabolic acidosis in humans. Swiss Med Wkly 2001;131:127-32
17. Janosi JB, Ramsland PA, Mott MR, Firth SM, Baxter RC, Delhanty PJ. The acid-labile subunit of the serum insulin-like growth factor-binding protein complexes. Structural determination by molecular modeling and electron microscopy. J Biol Chem 1999;274:23328-2
18. Conover CA, De Leon DD. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. J Biol Chem 1994;269:7076-80
19. Maki RG. Small is beautiful: insulin-line growth factors and their role in growth, development, and cancer. J Clin Oncol 2010;28:4985-5
20. Elmlinger MW, Wimmer K, Biemer E, Blum WF, Ranke MB, Dannecker GE. Insuline-like growth factor binding protein 2 is differentially expressed in leukaemic B- and T-cell lines. Growth Regul 1996;6:152-7
21. Hoeflich A, Reisinger R, Lahm H, et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001;61:8601-10
22. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor binding protein 2 is a candidate biomarker for PTEN status and P13 K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007;104:5563-8
23. Dunlap SM, Celestino J, Wang H, et al. Insulin- like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 2007;104:11736-41
24. Huynh H, Iizuka S, Kaba M, et al. Insulin-like growth factor-binding protein 2 secreted by a tumorigenic cell Line supports ex vivo expansion of mouse hematopoietic stem cells. Stem Cells 2008;26:1628-35
25. Baxter RC. Changes in the IGF-IGFBP axis in critical illness. Best Pract Res Clin Endocrinol Metab 2001;15:421-34
26. Green J, Goldberg R, Maor G. PTH ameliorates acidosis-induced adverse effects in skeletal growth centers: the PTH-IGF-I axis. Kidney Int 2003;63:487-500
27. Van Doorn J, Cornelissen AJ, Van Buul-Offers SC. Plasma levels of insulin-like growth factor binding protein-4 (IGFBP-4) under normal and pathological conditions. Clin Endocrinol (Oxf) 2001;54:655-64
28. Walenkamp MJ, Karperien M, Pereira AM, et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005;90:2855-64
29. van Duyvenvoorde HA, Kempers MJ, Twickler TB, et al. Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 2008;159:113-20